MUTATION OF THE VESICULAR MONOAMINE TRANSPORTER-1 GENE ALTERS ITS PROTEIN PRODUCT by Watson-Siriboe, Abena
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2010
MUTATION OF THE VESICULAR
MONOAMINE TRANSPORTER-1 GENE
ALTERS ITS PROTEIN PRODUCT
Abena Watson-Siriboe
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/77
  
  
College of Humanities and Sciences 
Virginia Commonwealth University  
 
 
 
This is to certify that the thesis prepared by Abena B. Watson-Siriboe entitled 
MUTATION OF THE VESICULAR MONOAMINE TRANSPORTER-1 GENE 
ALTERS ITS PROTEIN PRODUCT has been approved by his or her committee as 
satisfactory completion of the thesis or dissertation requirement for the degree of Masters 
of Science.  
 
 
 
 
Director of Thesis, Jennifer K. Stewart PhD., College of Humanities and Sciences  
 
 
 
Committee Member, John J. Ryan PhD., College of Humanities and Sciences 
 
 
 
Committee Member, Joseph H. Porter PhD., College of Humanities and Sciences 
 
 
 
Committee Member, Wan-Ling Chiu PhD., College of Humanities and Sciences 
 
 
 
Committee Member, Michael L. Fine PhD., College of Humanities and Sciences 
 
 
 
Fred M. Hawkridge, Interim Dean, College of Humanities and Sciences 
 
 
 
Dr. F. Douglas Boudinot, Dean of the School of Graduate Studies 
 
 
 
[Click here and type the Month, Day and Year this page was signed.] 
 
   
  
  
© Abena Barbara Watson-Siriboe May 2010 
All Rights Reserved 
 
 
 
 
 
 
 
 
   
   
 
  
 
MUTATION OF THE VESICULAR MONOAMINE TRANSPORTER-1 GENE 
ALTERS ITS PROTEIN PRODUCT  
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
by 
 
ABENA BARBARA WATSON-SIRIBOE 
BACHELORS OF SCIENCE, UNIVERSITY OF CALIFORNIA, RIVERSIDE, 2006 
MASTERS OF SCIENCE, VIRGINIA COMMONWEALTH UNIVERSITY, 2010 
 
 
 
 
Director: JENNIFER K. STEWART, PHD 
ASSOCIATE PROFESSOR, DEPARTMENT OF BIOLOGY 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2010
  
  
Acknowledgement 
 
 
 
 The author would like to acknowledge several people who have been integral to 
her success. First and foremost, I would like to thank Dr. Stewart.  Dr, Stewart has not 
only  been a great advisor, but has been integral in further molding a laid back budding 
scientist. But, she has been a great confidant, when things became a bit overwhelming. 
Secondly, I would like to thank my family. They were not only supportive of my move 
across the country, but patient as they watched my growth. I would also like to thank my 
committee; Dr. John Ryan , Dr. Joseph Porter, Dr. Michael Fine and Dr. Wan-Ling Chiu.  
I would like to give a very special thank you to the Chiu lab for not only teaching me new 
techniques, but for the use of their lab. Last but not least, many thanks is given the Dr. 
Krista Stenger and her lab for performing the western blots.  
 ii 
 
  
  
Table of Contents  
Page 
Acknowledgements............................................................................................................. ii 
List of Tables ......................................................................................................................v 
List of Figures .................................................................................................................... vi 
Chapter 
1 Introduction  
  A Brief Review: Vesicular Monoamine Transporters...................................1 
  The Schizophrenia Conundrum.....................................................................3 
                       Linkage of VMAT1 to Schizophrenia ..........................................................4 
2 Materials and Methods ......................................................................................6 
Cloning of hVMAT1 from Human Brain and Adrenal RNA .......................6 
Primers...........................................................................................................7 
Not I Digestion of pCMV6-XL5 Vector, Ligation into pCMV6-Neo Vector 
and Electrophoresis ...............................................................................10 
DNA Isolation from Agarose Gels ..............................................................10 
DNA Ligation and E.Coli Transformation..................................................11 
Plasmid Midi Prep and Determination of Insert Orientation ......................11 
Site Directed Mutagenesis of hVMAT1 in Neomycin 
Vector…………………………………………………………………13 
 iii 
 
  
  
Cells.............................................................................................................14 
Cell Transfection .........................................................................................15 
Membrane Preparation ................................................................................15 
Western Blotting..........................................................................................16 
VMAT Uptake Assay..................................................................................17 
3 Results..............................................................................................................18 
Site Directed Mutagenesis of hVMAT1-pCMV6-Neo ...............................18 
Creation of Stably Transfected Cell Lines ..................................................18 
Analysis of Serotoin Binding Activity ........................................................20 
4 Discussion........................................................................................................20 
Figures for Results .............................................................................................................23 
References..........................................................................................................................31 
 iv 
 
  
  
List of Tables 
Page 
Table 1: Reverse Transcriptase Polymerase Chain Reaction Primers. ................................7 
Table 2: Mutagenesis and Sequencing Primers. ................................................................14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
  
 
  
vi 
 
List of Figures 
Page 
Figure 1: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) ...........................8 
Figure 2: Reverse Transcriptase Polymerase Chain Reaction in Human Adrenal and Brain 
samples.................................................................................................................................9 
Figure 3: XMN-1 Digestion of hVMAT1-pCMV6-Neo to Determine Insert Orientation.13 
Figure 4: Site Directed Mutagenesis of  VMAT 1 sequences. ..........................................23 
Figure 5: Sequence of hVMAT1 DNA Obtained from Origene (A277C)... .....................24 
Figure 6: Sequence of hVMAT1 DNA Subject to Site Directed Mutagenesis (VMAT). .25 
Figure 7: Expression of VMAT1 Protein in CHO-K1 Transfected Cells..........................26 
Figure 8: Expression of VMAT1 Protein in CHO-K1 Transfected Cells..........................27 
Figure 9: Expression of hVMAT1 in Transfected Cells. ...................................................28 
Figure 10: Binding of Serotonin to Transfected hVMAT1 Protein...................................29 
Figure 11: Serotonin binding activity in Transiently Transfected COS-1 Cells................30 
 
  
Abstract 
 
MUTATION OF THE VESICULAR MONOAMINE TRANSPORTER-1 GENE 
ALTERS ITS PROTEIN PRODUCT 
 
By Abena Watson-Siriboe, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biology at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
Major Director:  Jennifer K. Stewart 
Associate Professor and Graduate Director, Department of Biology 
 
The vesicular monoamine transporter 1 (VMAT1) is essential for storage of monoamines, 
such as epinephrine and serotonin, in secretory vesicles of neuroendocrine cells.  Recently 
the VMAT1 protein was detected in human and mouse brain, and mutations of the 
VMAT1 gene at single DNA nucleotides (single nucleotide polymorphisms or SNPs) were 
associated with schizophrenia. In this study, Chinese hamster ovarian cells were stably 
transfected with either human VMAT1 DNA (GenBank: #NM_003053.1) or DNA with 
the Thr4Pro SNP, which results in a  threonine to proline change in amino acid number 4 
of the VMAT1 protein. Western blot analysis revealed that cells with the SNP produced 
immunoreactive human VMAT1 proteins of altered molecular size, suggesting that SNP 
Thr4Pro modifies either folding or processing of the VMAT1 protein. This finding is the 
first evidence for biochemical consequences of a mutation in the human VMAT1 gene. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
 
 A Brief Review of Vesicular Monoamine Transporters   
  The Solute Carrier gene family (SLC) consists of proteins that exhibit transporter 
function. Five SLC families are responsible for the transport of neurotransmitters, biogenic 
amines, ammonium and choline (9).  Vesicular neurotransmitter transporters play a role in 
the proper function of neural processes by regulating the storage and release of classic 
neurotransmitters such as norepinephrine, dopamine, and serotonin. (17) These 
transporters act by sequestering neurotransmitters into subcellular compartments, such as 
vesicles, resulting in a regulation of the transmitter signal as well as protection against the 
cytotoxic effects of such compounds.  Four types of vesicular neurotransmitter transporters 
have been identified: monoamine (VMAT), acetylcholine (VAchT), glutamate (VGluT) 
and GABA (VGAT) transporters (6).  These transporters share several characteristics, but 
the VMATs are of particular interest in this study. 
The vesicular monoamine transporters (VMATs) are part of the SLC18 gene family 
of vesicular amine transporters. Two isoforms have been identified, VMAT1 and VMAT2, 
which share a 60% sequence identity (5). Vesicular monoamine transporters are 
responsible for the sequestration of biogenic amines such as dopamine and norepinephrine 
within neuronal and endocrine cells (1). The structure of these transporters is characterized 
by twelve transmembrane domains resulting in a major 55 kDa molecule.(5). VMAT 1 has 
several substrates including dopamine, serotonin, norepinephrine and epinephrine. VMAT 
2 shares the same substrates but binds histamine with higher affinity (5). 
 
  
  
A vacuolar ATPase not directly associated with the transporter is responsible for 
producing a proton gradient across the vesicular membrane (5; 19). This proton gradient is 
utilized by the VMAT’s antiporter activity, exchanging two protons for each monoamine 
taken into the vesicle (19). Binding of the first proton to the transporter results in a 
conformational change,  exposing a high affinity binding site. Binding of the second proton 
results in the transport of the monoamine into the vesicular space (24). During an action 
potential, contents of the vesicle are discharged into the extracellular space by exocytosis 
(9).  
Although the VMATs share structural similarities, it was initially believed that they 
were located in different anatomical locations. Vesicular monoamine transporter 2 was 
initially identified in neurons of the brain and peripheral nerve endings, whereas; VMAT 1 
is associated with the adrenal medulla and neuroendocrine cells (5). Karen Brennan of the 
Stewart lab (VCU) detected VMAT1 within the mouse medulla/pons by reverse-
transcriptase polymerase chain reaction (RT-PCR). This novel finding is further 
complemented by the detection of VMAT1 in human postmortem brain tissue by both 
Western blots and real-time polymerase chain reaction (12).  Highest levels of human 
VMAT1 were identified in the substantia nigra, amygdala and hippocampus (13).  The 
novel discovery of VMAT1 in the human brain does not make the linkage of mutations in 
the transporter’s gene to bipolar disorder and schizophrenia suprising.  
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The Schizophrenia Conundrum  
 Schizophrenia is a multi-faceted neuropsychiatric disorder that affects 1% of the 
global population (16). The disorder is characterized by deteriorations in behavior, 
cognition and emotions (1). Symptoms of this disorder include: delusions, paranoid 
presentation and impaired memory (20). No single factor has been linked to susceptibility 
to developing the disorder. Combinations of environmental and genetic factors have been 
thought to increase susceptibility.  Factors such as maternal infection and nutritional 
deficiency have been linked to susceptibility as well as increased paternal age and fetal 
hypoxia (22). The most commonly supported factors are those that affect 
neurodevelopment and neurotransmitter regulation.  
  The gene “Disrupted in Schizophrenia 1” (DISC1) has been linked to several 
psychiatric disorders including bipolar disorder, autism and schizophrenia (23). DISC1 has 
many protein partners and often acts as a precursor to several pathways. The protein is 
highly expressed during development and is associated with several processes such as 
synaptic plasticity, neural migration and acting as a cytoskeletal scaffold protein (3; 10). 
The protein also has been identified at synapses. However, its role serves in the etiology of 
schizophrenia is  unknown.  
 The prevailing hypothesis for the etiology of schizophrenia focuses on dopamine, 
which  functions in motor activity, attention, stress and reward seeking behavior (14). 
Dysregulation of dopamine, in a regionally specific manner, may be linked to symptoms of 
schizophrenia such as psychosis. Upregulation of dopaminergic receptors has been 
hypothesized to play a large role in the dysregulation of this neurotransmitter (11). Several 
 3 
 
  
  
genes have been identified that play a role in dopamine dysregulation; however, these 
genes are rare and fail to account for a majority of schizophrenia cases.  
 Recent studies also implicate dysregulation of serotonin and specific serotonin 
receptors in schizophrenia. For example, the use of the drug iloperidone, an antagonist of 
both dopamine and serotonin receptors (15),  has been approved by the FDA for treatment 
of schizophrenia.  
 Schizophrenia has a non-Mendelian mode of inheritance (8). Although multiple 
susceptibility genes have been identified to have links to schizophrenia, these genes each 
have a small effect on the susceptibility to the disorder (8).  Alterations in genes such as 
DISC1 result in a several fold increase in risk of developing schizophrenia, but no single 
gene has been identified to definitively cause the disease upon mutation or deletion.  
 
 Linkage of VMAT1 to Schizophrenia 
   Chromosome 8 of the human genome is one of the best supported regions for 
susceptibility for schizophrenia and bipolar disorders. Approximately 8.5% of the genes 
contained in 8p are involved in cerebral development, plasticity and maintenance (21). Of 
the many genes on chromosome 8, one is of particular interest, SLC18A1 or the human 
VMAT1 gene.  
 Several single nucleotide polymorphisms have been identified in this gene. 
Sequenced DNA from schizophrenic Caucasian post-mortem brain tissue revealed a 
missense homozygous mutation in the SLC18A1. This single base mutation, A277C, 
resulted in a single amino acid change in the protein sequence conferring a threonine to 
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proline change at amino acid residue 4. This phenomena was seen in 21.4% of the 
schizophrenic group compared to 2.6% in the contol group (2). The first time VMAT1 was 
associated with susceptibility to schizophrenia. This finding was supported by the 
identification of the same SNP linked to schizophrenia in a subset of the Han Chinese 
population (4).  Furthermore, two other laboratories have reported associations of other 
mutations of the VMAT-1 gene with either schizophrenia or bipolar disorder in 
populations of European and Japanese descent (1; 18).  Specific effects of these single 
nucleotide polymorphisms on expression and biochemical properties of the human 
VMAT1 protein are not known. 
 The goals of this study were: (1) To stably transfect a cell line with expression 
vectors containing wild type human VMAT1 DNA or human VMAT1 DNA with the 
A277C mutation, and (2) To investigate effects of the A277C mutation on VMAT1 protein 
produced by the cells, specifically effects on immunoreactive protein observed on western 
blots and on the protein’s transport activity.  Investigation of biochemical consequences of 
VMAT1 mutations linked to schizophrenia may give further insight into the etiology of 
this complex disorder.  
  
  
Materials and Methods 
 
Cloning VMAT1 from human brain and adrenal RNA  
The initial procedure was to reverse transcribe human brain and adrenal VMAT1 
RNA to VMAT1 cDNA and amplify with PCR to obtain sufficient quantities of the DNA 
for cloning and transfection into cells.  Human brain and adrenal RNA were obtained from 
Stratagene (La Jolla, CA 540133, 540005). Three µg of each sample RNA were reverse 
transcribed with the SuperscriptTM Preamplification System (Invitrogen, Carlsbad, CA). 
Each reaction contained 2µl of the following 10X stock solutions:  0.5 µg oligo dT 
primers, 25 mM MgCl2, 0.1M DTT and 10X PCR buffer containing 20mM Tris-HCl and 
50 mM KCl. One µl of 10mM dNTP was added and enough DEPC water to result in a 
final volume of 21 µl. Reactants were incubated for 5 min  at 42° C prior to addition of 1 
µl Superscript RT II (200 U/µl) to sample tubes. Reactants were incubated for an 
additional 50 min  at 42° C in a thermocycler. The reaction was terminated by incubating 
tubes at 72° C for 15 min  then held at 4° C until placement on ice. Residual RNA was 
degraded using 2 U of RNase H (GibcoBRL) and incubated at 37° C for 20 min  
Polymerase Chain Reaction (PCR) 
Each PCR reaction contained 6 µl of RT product, 10 µl PCR buffer, 3 µl 50mM 
MgCl2, 2 µl 10 mM dNTP mix, 0.5 µl Taq DNA Polymerase (5 U/µl), 70.5 µl DEPC 
treated water, 8.0 µl primer mix (forward and reverse primers, 0.05 nmol/ul each). The 
cDNA was amplified for 40 cycles for the target and 30 cycles for β-actin (15 sec at 94 °C, 
15 sec at 56 °C and 30 sec at 72 °C). The reaction was held at 72 °C for 5 min , then at 4 
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°C until samples were stored at -20 °C. PCR for β-actin was performed as a control to 
determine the efficacy of the RT-PCR reaction. 
 
Primers 
PCR primers for RT-PCR were created using the Primer 3 program 
(http://frodo.wi.mit.edu/primer3/) and ordered from Invitrogen (Carlsbad, CA). Primers 
were designed to span at least 100 bp past the beginning and end of the target sequences 
(Table 1). PCR product was isolated by size by gel electrophoresis containing 1% agarose, 
1X TAE buffer (Invitrogen Carlsbad, CA) and 0.5 µl of Ethidium Bromide (10mg/ml). 
Electrophoresis was run for 0.5 hours at 90 V.  Human VMAT1 band was expected at 
1762 bp and human β-actin at 208 bp. Gels were visualized and photographed with the 
BioDoc-It Imaging System (UVP, LLC Upland, CA).  RT-PCR product was expected to 
produce a band size of approximately 1762 bp upon analysis by gel electrophoresis  
 
Table 1. Reverse Transcriptase Polymerase Chain Reaction Primers 
Primer 
Target Forward Primer 5'-3' Reverse Primer 5'-3' 
Expected Size Fragment 
(bp) 
hVMAT1 AAGTGAGTTTCCTTCGTCTGG GTCCCAGGGAAAGAGGTGGT 1762 
β-actin GGCCACGGCTGCTTC GTTGGCGTACAGGTCTTTGC 208 
 
 
As shown in Figures 1 and 2, RT-PCR of neither brain nor adrenal produced 
product that could be isolated from the gel for cloning.  Bands at the bottom of the gel 
represent unused primers.  β-actin controls for both adrenal (lane 6) and brain (lane 8) 
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samples produced robust bands at 208 bp (Figure 1).  DNA in lanes 3 and 5 appears to be 
represent many amplified fragments, suggesting a problem with the primers chosen for the 
RT reaction.  
 
                            
 
 
 
 
Figure 1. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).  AD = 
adrenal; BR = brain; No RT = reactions omitting the reverse transcriptase enzyme. 
Expected positions of hVMAT1 and β-actin products are shown on the right. Unused 
primers are at the bottom of No RT and No RNA lanes. The product is lane 7 may reflect 
primer dimers. 
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When the reaction was repeated with additional RNA samples and with 40 cycles 
of amplification the results did not improve.  Figure. 2 demonstrates the best of these 
results.  A faint band of approximately 1700 bp was observed in the brain sample. 
However, the yield for the reaction was too low for cloning purposes.  
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Figure 2. Reverse Transcriptase Polymerase Chain Reaction in Human Adrenal and 
Brain samples. RT-PCR  products from human brain and adrenal RNA are shown. AD= 
human adrenal gland. BR= human brain No RT= no reverse transcriptase. The expected 
position of hVMAT1 product is shown on the right.  Bands at the bottom of all lanes may 
reflect unused primers. 
 
 
Due to the difficulty in obtaining human VMAT1 cDNA from RNA, the human 
VMAT1 sequence was purchased from Origene (Rockville, MD) in the pCMV6-XL5 
vector, which also contained the ampicillin resistance gene.  In order to produce a stably 
transfected mammalian cell line, the VMAT1 cDNA insert had to be transferred to a vector 
containing both ampicillin and neomycin resistance as described below.  
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Transfer of hVMAT1 from pCMV6-XL5 to pCMV6-Neo Vector 
SLC18A1 (h-VMAT-1) in a pCMV6-XL5 vector was purchased from Origene 
(Rockville, MD SC122643). The plasmid was amplified in E. coli DH5α and purified with 
a midi-prep protocol by the Molecular Biology Core Laboratory (Virginia Commonwealth 
University), yielding 100 µl of product containing 2.623 µg/µl of plasmid.  One µg of 
plasmid DNA was digested with Not I (Invitrogen Carlsbad, CA).   A portion of the 
sample (1µl) was diluted to a concentration of 0.5 µg/µl in T10-E0.1 buffer (10mM 
TrisHcl and 0.1mM EDTA, pH 8.0), and 1µg of vector containing the insert was digested 
with Not I (Invitrogen Carlsbad, CA) according to manufacturer directions. Not I digestion 
product was separated by gel electrophoresis on a gel containing 1% agarose, 1X TAE 
buffer (Invitrogen) .  A 5 µl aliquot of digestion product and a 1 kb ladder were loaded into 
the gel and run at 90 V for approximately 0.5 hrs. Two resultant bands were identified, the 
empty vector (approximately 5800 bp) and insert (approximately 2770 bp).   
       Upon imaging, the target bands were identified and excised from the gel. Excised band 
weight ranged from 47-48 mg. Insert DNA was isolated from the excised band with the 
QIAquick gel extraction kit (Qiagen Valencia, CA) by the manufacturer’s protocol and 
dissolved in T10-E0.1 buffer. The resultant concentration was measured with the 
NanoDrop (SID-10135606, Thermo Scientific). 
 
DNA ligation and E. Coli transformation 
 Isolated insert was ligated into the pCMV6-Neo vector for the purpose of stable 
transfection. The ligation reaction consisted of : 1 µl 10X ligation buffer, 1ul pCMV6-Neo 
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vector, 2 µl purified insert, 2 µl T4 ligase (New England Biolabs Beverly, MA) and 
ultrapure water up to a final volume of 10µl.  The ligation was allowed to react for one 
hour at 37 ° C. Transformation of DH5α E. coli cells was performed with the heat shock 
method (50 μl of E. Coli cell culture was combined with 10 μl of ligation mix and allowed 
to incubate on ice for 20 min  The mixture was then incubated at 37° C for 4 min, then 
allowed to grow for 1.5 hours at 37° C while shaking. The resultant culture was transferred 
to an agar plate containing 100 mg/L ampicillin). Cultures were incubated at 37° C 
overnight. 
 
Plasmid Midi Prep and Determination of Insert Orientation  
Thirteen single colonies were selected and allowed to grow in LB broth containing 
100 µg/ml ampicillin overnight at 37 °C, then transferred to 1.5 ml tubes and centrifuged at 
16,0000 x G for 5 min  The pellet was resuspended in 0.3 ml of STET Buffer (8% Sucrose, 
5% Triton X-100, 50 mM EDTA, 50 mM Tris, pH 8.0) .  Lysozyme (25 µl at 20 U/ µl) 
was added, and tubes were placed in boiling water for 60 sec. Samples were then 
centrifuged at 16,000 x G at room temperature and the pellet removed.  Cold isopropanol 
(300 µl) was added to precipitate the DNA.  Samples were centrifuged at 16,000 x G at 
room temperature and pellets were washed with 70% ethanol. Pellets were then allowed to 
dry and resuspended in 20 µl T10-E0.1. 
 To determine insert orientation, a web based tool provided by New England 
Biolabs (Ipswich, MA) was used to identify restriction sites within the h-VMAT-1 
 11 
 
  
  
sequence (http://tools.neb.com/NEBcutter2/index.phpp). Isolated DNA was digested with 
Xmn1 (New England BioLabs Ipswich, MA). The plasmid was digested with 0.5 µl Xmn1 
(20U/μl) in 0.5 µl 10X enzyme buffer (New England Biolabs) supplemented with 0.5 BSA 
(100μg/ml) and 16 μl ultrapure water. The reaction was allowed to incubate for one hour. 
Reaction product was subjected to gel electrophoresis to visualize resultant bands 
conferring proper insert orientation.   Clones that contained the correct insert orientation 
presented bands similar in size at 5563 bp and 4145 bp (Figure 3).  Products were 
confirmed by gel electrophoresis in five of thirteen samples. These plasmids were selected 
for site directed mutagenesis and sequencing. 
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12,216 bp 
2,036  bp 
3,054 bp 
1,636  bp 
 
 
Figure 3.  XMN-1 Digestion of hVMAT1-pCMV6-Neo to Determine Insert 
Orientation.  Human VMAT1 insert was removed from the original vector with the Not-1 
restriction enzyme. The insert was then ligated into the pCMV6-Neo vector with the T4 
ligase.. Orientation of the insert was determined by digestion of the plasmid with XMN-1 
restriction enzyme. Correct orientation yielded bands of 5563 bp and 4145 bp, whereas, 
incorrect orientation of the insert yielded bands of 7383 and 2325 bp when analyzed by gel 
electrophoresis. 
Colony #:  1       2       3       4       5       6       7        8        9       10      11      12      13 
1,018 bp 
 
 
Site Directed Mutagenesis of hVMAT1 in Neomycin Vector 
In order to create the nucleotide polymorphism of interest, site directed 
mutagenesis was performed with the QuickChange II XL Site Directed Mutagenesis Kit     
( #200521, Stratagene La Jolla, CA) according to manufacturer’s protocol.  Primers for 
mutagenesis were determined with the QuickChange Primer Design Program 
(http://www.stratagene.com/sdmdesigner/default.aspx) and purchased from (Invitrogen). 
Primers spanned the target area and are represented in Table 2.   
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Table 2. Mutagenesis and Sequencing Primers 
Primer Target Forward Primer 5'-3' Reverse Primer 5'-3'  
Mutagenesis 
C277A GGCCATCACCATGCTCCGGACCATTCTG CCGGTAGTGGTACGAGGCCTGGTAAG 
  GGACTTTCCAAAATGTCG ATTAGGACAAGGCTGGTGGG 
  CCTGACCTCCCTGTGTGTTCC GGCCGGACTGGGGCAGTCTTCCC 
  CCCTTACATCCTGGTGGCTGC CAGACGAAGGAAACTCAC 
Sequencing 
Primers GGTGGCTGTGTTCCCTAATC CCCCAAGGCCAGGCCCC 
  GCCCTCGCCTCTCCTGCC CCTCCCCCAGAGGAAATTCC 
  CGGAAGAGTGTTACCC GAGGGTACACTCTTTCCG 
  GGCCCGAACCCTTCAAGGC CCTCCCCCAGAGGAAATTCC 
 
 
Cells 
The COS-1 kidney fibroblast cell line was obtained from American Type Culture 
Collection (ATCC # 30-2002, Manassas, VA). Cells were maintained at 37° C with 5% 
CO2 in DMEM medium (# 30-2002, ATCC) containing 4 mM L-glutamine, 4.5 g/L 
glucose and 1.5g/L sodium bicarbonate. COS-1 medium is supplemented with 10% heat 
inactivated fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin. 
CHO K1 cells were obtained from Dr. Bruno Steiger, Geneva Switzerland and 
maintained at 37° C with 5% CO2 in DMEM medium (#11885-092, Invitrogen) containing 
4mM L-glutamine, 5mM glucose and 0.4 mM glycine. Medium was supplemented with 
10% heat inactivated fetal bovine serum, 50 μg/ml L-proline, 100 units/ml penicillin and 
100 units/ml streptomycin. Because CHO cells were transfected with plasmids containing 
a gene that confers neomycin resistance, these cells were maintained in a medium 
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supplemented with 500 μg/ml Geneticin (# 10131-035, Invitrogen). As the cells grow and 
divide, the medium selects against cells that do not have the plasmid.  
 
Cell Transfection   
Cells were transfected with VMAT-1 cDNA or vector alone by electroporation as 
described by Finn et. al. COS-1 cells were grown to confluency in T-75 flasks and fed 
fresh medium 24 hours prior to electroporation. The day of electroporation, cells were 
rinsed with calcium-and magnesium-free phosphate buffered saline (PBS), detached with 
0.25% trypsin and medium containing serum added to inactivate trypsin.  Cells were 
pelleted by centrifugation (500 x g for 5 min at 4 C). COS 1 cells were resuspended in 700 
μl of warm PBS containing calcium and magnesium (Invitrogen), whereas CHO cells were 
resuspended in ice-cold PBS containing calcium and magnesium (Invitrogen) and 
remained on ice for 10 min prior to electroporation. The cell suspension and 15 μg of DNA 
was transferred to a 0.4 cm gap cuvette in the Gene Pulser II (Bio-Rad, Hercules, CA). 
Suspension and DNA were electroporated at 0.4 kV and 950 μF. CHO cells were placed on 
ice for 10 min prior to replating. Cells were replated in a T-75 flask containing fresh 
medium and incubated prior to membrane preparation for transport assays. 
 
Membrane Preparation 
The third day after electroporation, cells were rinsed with PBS. After removal of 
PBS, lysis buffer (containing 0.32 M sucrose, 10 mM Hepes adjusted to pH 7.4 with 1M 
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KOH) supplemented with proteolytic inhibitors as described by Finn et. al (7), was added 
to the T-75 flask. Cells were then scraped with a cell scraper into the lysis buffer. The cell 
suspension was pelleted (500 x g for 5 min) and the supernatant removed. Cells were then 
resuspended in 100 μl lysis buffer. The cell suspension was homogenized 40 strokes with a 
Dounce homogenizer, and homogenate was pelleted at 3500 x g for 10 min at 5 ° C. The 
supernatant was taken and aliquoted, and the pellets were resuspended in 150 µl of SH 
buffer with proteolytic inhibitors and aliquoted. Total protein for the supernatant was 
measured with the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Aliquots were stored at 
-70 ° C until assayed for VMAT-1 activity. 
 
Western Blotting 
CHO-K1 and COS-1 cells membranes were prepared as described above. With the 
help of Dr. Krista Stenger (University of Richmond, Richmond, VA), proteins were 
separated by electrophoresis on 10% polyacrylamide gels and transferred to nitrocellulose. 
Blots were incubated overnight at 4 ° C or for 1 hour at room temperature in blocking 
solution containing Tris buffered saline, 0.1% Tween-20 (TBST) and 5% dry milk, and 
subsequently incubated overnight at 4 ° C with a primary goat polyclonal anti-VMAT-1 
antibody (C-19; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, sc-7718) diluted 1:200 in 
TBST. This antibody targets the COOH-terminal end of human VMAT1. Blots were 
washed with TBST and incubated with a 1:7500 dilution of bovine anti-goat                 
IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology Inc., sc-2378) for 1 hour at 
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room temperature.  The blots were visualized with enhanced chemiluminesence 
(Amersham, Biosciences, UK).  Blots were stripped using Re-Blot Plus Mild for 15 min, 
blocked 2X for 5 min with blocking solution and probed again with a mouse monoclonal 
anti-actin antibody (clone AC-15; Sigma) diluted 1:5000 in TBST for 1 hour at room 
temperature.  Blots were washed with TBST and incubated with a 1:7500 dilution of goat 
anti-mouse IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology Inc., sc-2031) 
for 1 hour at room temperature and visualized as described above. 
A blocking peptide was used to neutralize the reactivity with AB #1:  A five-fold 
excess of peptide was incubated with the appropriate dilution of antibody in 500 μl of 
TBST overnight at 4 º C with agitation.  Following neutralization the antibody/peptide 
mixture was added to the appropriate final working volume of TBST as a substitute for the 
primary antibody alone, and the western blot procedure was performed as usual. 
 
VMAT Uptake Assay 
Each assay contained 30 μg of cell protein, 5 mM ATP and 20 nM 3H labeled 
serotonin [3H-5HT] (Amersham Biosciences, Piscataway, NJ) in a final volume of 200 μl 
uptake buffer. Tubes were then incubated at 29 ° C for 10 min, except in preliminary time 
course experiments. The reaction was  terminated with 1.5 ml cold SH buffer and filtered 
rapidly through 0.2 μm Supor 200 membrane filters (Pall/Gellman #60300) in a Millipore 
sampling manifold. The reaction tubes were rinsed with an additional 1.5 ml cold SH 
buffer and dispensed to the proper filter. Filters were transferred to a scintillation vial 
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containing 5 ml of ScintiSafe scintillation fluid (Fisher Scientific, Atlanta, GA) and 
reactivity determined with a Beckman LS6000IC scintillation counter.  The reaction 
kinetics were analyzed with Prism software (GraphPad Prism, La Jolla, CA). 
 
Statistics 
 Statistical analysis was performed using the GraphPad Prizm4 program ( GraphPad 
Software Inc  La Jolla, CA).  
 
Results 
 
Site Directed Mutagenesis of hVMAT1-pCMV6-Neo 
 A BLAST alignment with a GenBank reference sequence for human VMAT-1 
(GenBank # NM_003053.1) revealed that the Origene human VMAT1 sequence contained 
the A277C SNP of interest. The SNP results a cytosine (c) to adenine (a) change resulting 
in a threonine rather than a proline at residue 4 of the protein.  To determine if this finding 
was correct, a sample of the Origene human VMAT1 was sequenced by the Sequencing 
Core at VCU (Figure 4A).  Indeed, the A277C SNP was found to be present in the human 
DNA provided by Origene (Rockville, MD SC122643).  Site directed mutagenesis to 
revert the C to A, and the mutagenesis was verified to be successful and reflected wild type 
human VMAT1 (VMAT, Figure 4B).  Both VMAT1 and A277C were fully sequenced 
(Figures 5 and 6).  
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Creation of Stably Transfected Cell Lines 
 Western blot analysis confirmed the presence of hVMAT1 protein in transfected 
cell extracts (Figures 7 and 8). Three immunoreactive bands at 55, 58 and 72 kDa 
respectively were detected in the pellet fraction of CHO wild type cells. This  indicates the 
presence of cross-reactivity of hamster VMAT1 with the antibody targeting the human 
VMAT1 C-terminus. In cells transfected with human VMAT1 carrying the A277C 
mutation, the 55 kDa band was either absent (Figure 7) or reduced in the protein pellet 
fraction (Figure 8).   The 58 kDa band was more evident, however, in cells with the A277C 
mutation than in non-transfected wild type cells, suggesting the transfection was 
successful.  Cells transfected with human VMAT1 matching the reference sequence 
(GenBank: #NM_003053.1; indicated as VMAT in Figures 7 and 8) exhibited over-
expression of the 58 kDa band and slightly increased expression of the 55 kDa band over 
that observed in wild type CHO cells.  
Results of densitometric analysis of the the 55 and 58 kDa bands are shown in 
Figure 9 .  A277C pellet produced a 58 kDa band 0.5 times the density of itsrespective 
actin band. A277C pellet did not produce a measurable 55 kDa band. VMAT1 protein 
pellet produced bands at 55 kDa and 58 kDa, which showed a density of 1.6 and 0.8 times 
their respective actin bands. VMAT1 supernatant produced one band at 58 kDa which 
measured 0.8 times the density of the actin band. WT CHO supernatant did not produce 
measurable band at 55 or 58 kDa. WT pellet however, produced bands at 55 and 58 kDa. 
These bands measured 0.36 and 0.3 times the respective actin bands.  
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Analysis of Serotoin Binding Activity 
 
 Assay of serotonin binding activity of protein from permanently transfected and 
wild-type CHO cells or transiently transfected and wild type COS1 cells was analyzed by 
radioactive ligand binding assay. Binding activity of either supernatant or pellet protein 
fractions from transfected CHO and COS1 cells showed no statistical difference in activity 
when compared to protein from wild-type cells (Figures 10 and 11).  
 
 
 
 
Discussion 
.  
 The A277C mutation has been linked to schizophrenia in more than one nationality 
by several laboratories. The effect of this mutation on the function and expression of 
VMAT1 is unknown. This study was one of the first to investigate the effect of SNPs in 
the human VMAT1 gene on cellular expression of the VMAT1 protein. DNA was obtained 
from a manufacturer and found to contain the A277C SNP of interest.  Site directed 
mutagenesis was successfully performed, resulting in a sequence matching the reference 
sequence (GenBank: #NM_003053.1) for use in stable transfections.  
Transfection of human VMAT1 into CHO cells was successful as determined by 
Western blot analysis. Western blotting also revealed several points of interest.  In cells 
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with the A277C SNP, immunoreactive VMAT1 proteins (58 and 72 kDa) were detected, 
but expression of the expected protein band at 55 kDa was either reduced or absent. This 
does not appear to be due to failure of the antibody to bind to the mutated region of the 
sequence, as the A277C mutation is near the NH2 terminus of the protein, and the antibody 
targets the COOH terminus.  Alternatively, lack of the 55 KDa VMAT1 may reflect other 
effects on VMAT1 processing that made the protein more vulnerable to degradation. This 
hypothesis can be explored by immunoprecipitation and subsequent western analysis for 
ubiquitinated VMAT1.  
Binding assays revealed no difference in activity between any cell treatment: WT, 
A277C or VMAT1. Both pellet and supernatant were tested for the activity of VMAT1. 
Wild type cells showed relatively high binding of tritiated serotonin. The Western analysis 
revealed the presence of imunnoreactive hamster VMAT1 in the pellet fraction of wild-
type cells, accounting for the high binding. However, use of positive controls did not yield 
results observed in the past. This confirms that the assay procedure may need to be revised. 
Also, we cannot exclude the possibility that wild type or mutated human VMAT1 that is 
expressed in CHO cells may have very little activity. This hypothesis cannot be confirmed 
without further study.  
This study has provided a preliminary base for performing future experiments. 
Additional transport assays would provide great insight into the effects of mutation on 
activity of human VMAT1. Despite extensive troubleshooting of the transport assay, 
measurable VMAT1 activity was not seen. The assay protocol may have to be revised. A 
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different transport assay utilizing intact cells may provide a better measure of VMAT1 
activity in transfected cells.  
Further Western blot analysis utilizing various molecular weight ladders and 
antibodies are required to obtain a clearer picture of the expression of VMAT1 within 
transfected cells. The amount of ubiquitinated VMAT1 within A277C samples could be 
tested in order to determine whether the A277C VMAT1 is in fact degraded quickly after 
formation. In order to achieve this goal, proteasome activity in cells would have to be 
inhibited.  
This study provides the first evidence of the affect of the A277C SNP on the 
formation of the VMAT1 protein in mammalian cells. Stably transfected cell lines 
containing either VMAT1 or A277C have been successfully created. It was determined 
that the A277C SNP results in a protein change of VMAT1 eliminating the 55 kDa product 
as determined by western blot analysis. This novel study provides a great base for future 
study of the A277C mutation.  
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Figures 
 
 
 
 
A 
 
 
A277C   ATCACCATGCTCCGGCCCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG  570 
        ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
hVMAT1  ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG  321 
 
 
 
B 
 
VMAT    ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG  563 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
hVMAT1  ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG  321 
 
 
 
 
Figure 4.  Site Directed Mutagenesis of  VMAT 1 sequences.  (A) Sequencing of the 
VMAT1 DNA provided by Origene (Rockville, MD) indicated the presence of SNP 
A277C highlighted in pink.  The sequence is aligned with the hVMAT1 reference 
sequence (GenBank NM_003053.1)   (B) The Origene DNA was subjected to site directed 
mutagenesis, which reverse-mutated  A277C to a VMAT sequence matching the hVMAT1 
reference sequence(GenBank: # NM_003053.1) as highlighted in yellow.   
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      92 gctaacagct gccaatacct cactgagtg 
      121 cctcacacca acatgggctc caagtgagtt tccttcgtct gggcagactc cctcccctct 
      181 tccataaagg ctgcaggaga cctgtagctg tcacaggacc ttccctaaga gcccgcaggg 
      241 aaagactgcc ccagtccggc catcaccatg ctccggccca ttctggatgc tccccagcgg 
      301 ttgctgaagg aggggagagc gtcccggcag ctggtgctgg tggtggtatt cgtcgctttg 
      361 ctcctggaca acatgctgtt tactgtggtg gtgccaattg tgcccacctt cctatatgac 
      421 atggagttca aagaagtcaa ctcttctctg cacctcggcc atgccggaag ttccccacat 
      481 gccctcgcct ctcctgcctt ttccaccatc ttctccttct tcaacaacaa caccgtggct 
      541 gttgaagaaa gcgtacctag tggaatagca tggatgaatg acactgccag caccatccca 
      601 cctccagcca ctgaagccat ctcagctcat aaaaacaact gcttgcaagg cacaggtttc 
      661 ttggaggaag agattacccg ggtcggggtt ctgtttgctt caaaggctgt gatgcaactt 
      721 ctggtcaacc cattcgtggg ccctctcacc aacaggattg gatatcatat ccccatgttt 
      781 gctggctttg ttatcatgtt tctctccaca gttatgtttg ctttttctgg gacctatact 
      841 ctactctttg tggcccgaac ccttcaaggc attggatctt cattttcatc tgttgcaggt 
      901 cttggaatgc tggccagtgt ctacactgat gaccatgaga gaggacgagc catgggaact 
      961 gctctggggg gcctggcctt ggggttgctg gtgggagctc cctttggaag tgtaatgtac 
     1021 gagtttgttg ggaagtctgc acccttcctc atcctggcct tcctggcact actggatgga 
     1081 gcactccagc tttgcatcct acagccttcc aaagtctctc ctgagagtgc caaggggact 
     1141 cccctcttta tgcttctcaa agacccttac atcctggtgg ctgcagggtc catctgcttt 
     1201 gccaacatgg gggtggccat cctggagccc acactgccca tctggatgat gcagaccatg 
     1261 tgctccccca agtggcagct gggtctagct ttcttgcctg ccagtgtgtc ctacctcatt 
     1321 ggcaccaacc tctttggtgt gttggccaac aagatgggtc ggtggctgtg ttccctaatc 
     1381 gggatgctgg tagtaggtac cagcttgctc tgtgttcctc tggctcacaa tatttttggt 
     1441 ctcattggcc ccaatgcagg gcttggcctt gccataggca tggtggattc ttctatgatg 
     1501 cccatcatgg ggcacctggt ggatctacgc cacacctcgg tgtatgggag tgtctacgcc 
     1561 atcgctgatg tggctttttg catgggcttt gctataggtc catccaccgg tggtgccatt 
     1621 gtaaaggcca tcggttttcc ctggctcatg gtcatcactg gggtcatcaa catcgtctat 
     1681 gctccactct gctactacct gcggagcccc ccggcaaagg aagagaagct tgctattctg 
     1741 agtcaggact gccccatgga gacccggatg tatgcaaccc agaagcccac gaaggaattt 
     1801 cctctggggg aggacagtga tgaggagcct gaccatgagg agtagcagca gaaggtgctc 
     1861 cttgaattca tgatgcctca gtgaccacct ctttccctgg gaccagatca ccatggctga 
     1921 gcccacggct cagtgggctt cacatacctc tgcctgggaa tcttctttcc tcccctccca 
     1981 tggacactgt ccctgatact cttctcacct gtgtaacttg tagctcttcc tctatgcctt 
     2041 ggtgccgcag tggcccatct tttatgggaa gacagagtga tgcaccttcc cgctgctgtg 
     2101 aggttgatta aacttgagct gtgacgggtt ctgcaagggg tgactcattg catagaggtg 
     2161 gtagtgagta atgtgcccct gaaaccagtg gggtgactga caagcctctt taatctgttg 
     2221 cctgattttc tctggcatag tcccaacaga tcggaagagt gttaccctct tttcctcaac 
     2281 gtgttctttc ccgggttttc ccagccgagt tgagaaaatg ttctcagcat tgtcttgctg 
     2341 ccaaatgcca gcttgaagag ttttgttttg ttttttttcc atttattttt tttttttaat 
     2401 aaagtgagtg atttttctgt ggctaaatct agagctgcta aaagggcttt accctcagtg 
     2461 aaaagtgtct tctattttca ttatctttca gaaacaggag cccatttctc ttctgctgga 
     2521 gttattgaca ttctcctgac ctcccctgtg tgttcctacc ttttctgaac ctcttagact 
     2581 cttagaaata aaagtagaag aaagacagaa aaaataactg attagaccca agatttcatg 
     2641 ggaagaagtt aaaagaaact gccttgaaat ccctcctgat tgtagatttc ctaataggag 
     2701 gggtgtaatg tgacattgtt catacttgct aataaataca ttattgcct 
 
 
Figure 5. Sequence of hVMAT1 DNA Obtained from Origene (A277C). After 
obtaining the plasmid, it was sent to the sequencing core (VCU). It was determined that the 
plasmid contained the SNP of interest and the remainder of the sequence was identical to 
human VMAT1 (Gen Bank: #NM_003053.1). Start and stop codons are highlighted.  
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      92  gctaacagct gccaatacct cactgagtg 
      121 cctcacacca acatgggctc caagtgagtt tccttcgtct gggcagactc cctcccctct 
      181 tccataaagg ctgcaggaga cctgtagctg tcacaggacc ttccctaaga gcccgcaggg 
      241 aaagactgcc ccagtccggc catcaccatg ctccggacca ttctggatgc tccccagcgg 
      301 ttgctgaagg aggggagagc gtcccggcag ctggtgctgg tggtggtatt cgtcgctttg 
      361 ctcctggaca acatgctgtt tactgtggtg gtgccaattg tgcccacctt cctatatgac 
      421 atggagttca aagaagtcaa ctcttctctg cacctcggcc atgccggaag ttccccacat 
      481 gccctcgcct ctcctgcctt ttccaccatc ttctccttct tcaacaacaa caccgtggct 
      541 gttgaagaaa gcgtacctag tggaatagca tggatgaatg acactgccag caccatccca 
      601 cctccagcca ctgaagccat ctcagctcat aaaaacaact gcttgcaagg cacaggtttc 
      661 ttggaggaag agattacccg ggtcggggtt ctgtttgctt caaaggctgt gatgcaactt 
      721 ctggtcaacc cattcgtggg ccctctcacc aacaggattg gatatcatat ccccatgttt 
      781 gctggctttg ttatcatgtt tctctccaca gttatgtttg ctttttctgg gacctatact 
      841 ctactctttg tggcccgaac ccttcaaggc attggatctt cattttcatc tgttgcaggt 
      901 cttggaatgc tggccagtgt ctacactgat gaccatgaga gaggacgagc catgggaact 
      961 gctctggggg gcctggcctt ggggttgctg gtgggagctc cctttggaag tgtaatgtac 
     1021 gagtttgttg ggaagtctgc acccttcctc atcctggcct tcctggcact actggatgga 
     1081 gcactccagc tttgcatcct acagccttcc aaagtctctc ctgagagtgc caaggggact 
     1141 cccctcttta tgcttctcaa agacccttac atcctggtgg ctgcagggtc catctgcttt 
     1201 gccaacatgg gggtggccat cctggagccc acactgccca tctggatgat gcagaccatg 
     1261 tgctccccca agtggcagct gggtctagct ttcttgcctg ccagtgtgtc ctacctcatt 
     1321 ggcaccaacc tctttggtgt gttggccaac aagatgggtc ggtggctgtg ttccctaatc 
     1381 gggatgctgg tagtaggtac cagcttgctc tgtgttcctc tggctcacaa tatttttggt 
     1441 ctcattggcc ccaatgcagg gcttggcctt gccataggca tggtggattc ttctatgatg 
     1501 cccatcatgg ggcacctggt ggatctacgc cacacctcgg tgtatgggag tgtctacgcc 
     1561 atcgctgatg tggctttttg catgggcttt gctataggtc catccaccgg tggtgccatt 
     1621 gtaaaggcca tcggttttcc ctggctcatg gtcatcactg gggtcatcaa catcgtctat 
     1681 gctccactct gctactacct gcggagcccc ccggcaaagg aagagaagct tgctattctg 
     1741 agtcaggact gccccatgga gacccggatg tatgcaaccc agaagcccac gaaggaattt 
     1801 cctctggggg aggacagtga tgaggagcct gaccatgagg agtagcagca gaaggtgctc 
     1861 cttgaattca tgatgcctca gtgaccacct ctttccctgg gaccagatca ccatggctga 
     1921 gcccacggct cagtgggctt cacatacctc tgcctgggaa tcttctttcc tcccctccca 
     1981 tggacactgt ccctgatact cttctcacct gtgtaacttg tagctcttcc tctatgcctt 
     2041 ggtgccgcag tggcccatct tttatgggaa gacagagtga tgcaccttcc cgctgctgtg 
     2101 aggttgatta aacttgagct gtgacgggtt ctgcaagggg tgactcattg catagaggtg 
     2161 gtagtgagta atgtgcccct gaaaccagtg gggtgactga caagcctctt taatctgttg 
     2221 cctgattttc tctggcatag tcccaacaga tcggaagagt gttaccctct tttcctcaac 
     2281 gtgttctttc ccgggttttc ccagccgagt tgagaaaatg ttctcagcat tgtcttgctg 
     2341 ccaaatgcca gcttgaagag ttttgttttg ttttttttcc atttattttt tttttttaat 
     2401 aaagtgagtg atttttctgt ggctaaatct agagctgcta aaagggcttt accctcagtg 
     2461 aaaagtgtct tctattttca ttatctttca gaaacaggag cccatttctc ttctgctgga 
     2521 gttattgaca ttctcctgac ctcccctgtg tgttcctacc ttttctgaac ctcttagact 
     2581 cttagaaata aaagtagaag aaagacagaa aaaataactg attagaccca agatttcatg 
     2641 ggaagaagtt aaaagaaact gccttgaaat ccctcctgat tgtagatttc ctaataggag 
     2701 gggtgtaatg tgacattgtt catacttgct aataaataca ttattgcct 
 
 
 
Figure 6.  Sequence of hVMAT1 DNA Subject to Site Directed Mutagenesis (VMAT).  
After site directed mutagenesis, the plasmid was sent to the sequencing core (VCU). It was 
determined that he plasmid was mutated successfully to match the reference sequence and 
the remainder of the sequence was identical human VMAT1 (GenBank: #NM_003053.1). 
Start and stop codons are highlighted. 
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Figure 7.  Expression of VMAT1 Protein in CHO-K1 Transfected Cells. Stably 
tranfected CHO-K1 cell lines containing either the A277C mutation (Origene sequence) or 
the reference VMAT1 sequence created with site-directed mutagenesis. S1 denotes cell 
lysate supernatant, and P1 denotes the 3500 x G cell lysate pellet. WT denotes wild type 
CHO cell protein (cells not transfected). 
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Figure 8.  Expression of VMAT1 Protein in CHO-K1 Transfected Cells.  (S1 = 
supernatant and P1 =pellet) Stably tranfected CHO-K1 cell lines expressed either the 
A277C mutation (Origene sequence) or the wild type VMAT1 sequence created with site-
directed mutagenesis. S1 denotes cell lysate supernatant. P1 denotes cell lysate pellet. WT 
denoted wild type CHO protein. The above blot utilized cell protein from a separate 
harvest from protein in Figure 7.  
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Figure 9. Expression of hVMAT1 in Transfected Cells. CHO cells were transfected 
with either the A277C or VMAT1 plasmids and harvested when confluent. Cell lysate 
supernatant and pellet were subject to western blot analysis by Dr. Krista Stenger 
(University of Richmond). Density of resultant bands were measured with ImageJ (NIH) 
and compared to their respective β-actin bands.  
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Figure  10.  Binding of Serotonin to Transfected hVMAT1 Protein.  CHO-K1 cells 
were stably transfected with either the A277C or VMAT1 plasmids. Cell lysate pellet (P1) 
protein was incubated for 10 min in the presence of 5mM ATP and 20 nM tritiated 
serotonin.  
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 *         *          * 
 
 
Figure 11. Serotonin binding activity in transiently transfected COS-1 Cells.  COS1 
cells were transiently transfected with either the A277C or VMAT1 plasmids. Cell lysate 
pellet and supernatant protein activities were analyzed by radioactive ligand binding assay. 
Cell supernatant and pellet demonstrated significant differences in activity despite cell 
treatment (* p > 0.05 compared to all S1 fractions). No significant differences were 
observed in activity among wt and transfected cells.   
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